Company attributes
Industry
B2X
0
CEO
Number of Employees (Ranges)
11 – 500
Email Address
info@vaxil-bio.com
enteryour@addresshere.com0
Full Address
3 Pinhas Sapir Street, 3rd Floor, “Weizmann Science Park”, 74140, Rehovot, Israel0
First Canadian Place, 34th Floor, 100 King Street W., Toronto Ontario. M2N 6N4 Canada0
Founded Date
2007
Competitors
Stock Symbol
VXL
Exchange
Other attributes
Company Operating Status
Active
Vaxil Bio Therapeutics is an Israel-based immuno-oncology biotechnology company specializing in cancer and infectious diseases. It conducts research and development of medical solutions for its studied illnesses. Its lead product, IMMUCIN, is for immunotherapy purposes and has been given orphan drug status from both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
COVID-19
In 2020, the company utilized its VaxHit bioinformatics platform to create a vaccine candidate for COVID-19 using signal peptide technology. The candidate's design has been successful in testing a tuberculosis vaccine.
Timeline
No Timeline data yet.
